Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marie-Agnès Azerad is active.

Publication


Featured researches published by Marie-Agnès Azerad.


Translational Research | 2014

Transfusion support of autoimmune hemolytic anemia: how could the blood group genotyping help?

Hanane El Kenz; André Efira; Phu-Quoc Le; Claire Thiry; Joseph Valsamis; Marie-Agnès Azerad; Francis Corazza

Conventional pretransfusion testing based on hemagglutination assays can be challenging for patients with autoimmune hemolytic anemia (AIHA) because of the presence of auto-antibodies. It has been suggested that deoxyribonucleic acid-based methods could be more efficient in the selection of antigen-matched red blood cell units in those settings. Because of the high risk of alloimmunization of these patients and the labor-intensive nature of adsorption techniques, we decided to evaluate the feasibility of selecting antigen-matched units on the basis of RBC genotyping. We included in our routine RBC genotyping program samples from 7 patients with AIHA presenting a strongly positive direct antiglobulin test. This made the routine compatibility tests difficult. Most patients had previously received transfusions because of warm AIHA. Matched donor units were selected according to the genotype. For all but 1 patient, blood group genotyping could be done on time to allow antigen-matched transfusion. Four patients received antigen-matched red blood cell units based on RBC genotyping and for 1 patient the fact that no matched units were available led us to postpone the transfusion. After each transfusion, the recovery was recorded and considered satisfactory for all transfused patients.


British Journal of Haematology | 2018

Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial

Joep W. R. Sins; Karin Fijnvandraat; Anita W. Rijneveld; Martine B. Boom; Jean-Louis Kerkhoffs; Alfred H. van Meurs; Marco R. De Groot; Harriët Heijboer; Marie-Françoise Dresse; Phu-Quoc Le; Philippe Hermans; Anna Vanderfaeillie; Eric Van Den Neste; Fleur Samantha Benghiat; Rachel Kesse-Adu; André Efira; Marie-Agnès Azerad; Corianne A.J.M. de Borgie; Bart J. Biemond

N.J.S. collected and analysed the data and wrote the manuscript; H.K. designed the study and treated patients; E.J., J.E.C, D.A.T, M.E.R., N.D., Y.A., M.K., P.K., W.G.W. and C.D.D. treated patients; C.B., D.M. and M.A.R. collected and analysed the data; F.R. designed the study, collected and analysed the data, treated patients and wrote the manuscript. All authors approved the final version of the manuscript.


British Journal of Haematology | 2018

Added value of speckle tracking in the evaluation of cardiac function in patients with sickle cell disease

Marielle Morissens; Jose Castro Rodriguez; Marie-Agnès Azerad; Tatiana Besse-Hammer; André Efira

Speckle tracking echocardiography is a new means of evaluating cardiac function. The principle of speckle tracking is to measure myocardial strain, based on local shortening, lengthening and thickening of the muscles. It has been proposed that the left ventricle global longitudinal strain (LV-GLS) could be a useful tool for the detection of early systolic dysfunction in patients under cardiotoxic chemotherapy (Thavendiranathan et al, 2014). Moreover, the high reproducibility of the LV-GLS represents an advantage over the left ventricle ejection fraction (LVEF) (King et al, 2016; Medvedofsky et al, 2017). Compared to the LVEF, the LV-GLS is less affected by changes in loading conditions, which makes it a potentially useful tool in patients with sickle cell disease (SCD), due to the chronic overload associated with SCD. However, in this population, studies are rare and results are conflicting (Ahmad et al, 2012; Sengupta et al, 2012; Barbosa et al, 2014; Hammoudi et al, 2014). The primary aim of our study was to determine whether the LV-GLS was abnormal in a monocentric population of adults with SCD, compared to a matched population of healthy individuals. The secondary aim was to investigate correlations between the echocardiographic parameters and the biological and clinical evaluations of patients with SCD. The institutional Ethics Committee approved the protocol. All patients provided informed consent. We prospectively included 37 patients with SCD and 34 healthy, ageand sex-matched controls. The patient and control groups were similar in age (31 10 years vs. 32 10 years, respectively). The LVEF was significantly lower in the SCD group than in the control group (Teicholz: 61 8% vs. 67 6%; P = 0 05; Simpson: 61 9% vs. 69 3%; P < 0 05; Table I). However, only one patient had a Simpson LVEF < 50%. The left ventricular (LV) mass and LV end diastolic diameter (LVEDD) were higher in the patient group (LV mass: 107 g/m vs. 70 g/m, P < 0 05 and LVEDD: 53 mm vs. 46 mm; P < 0 05). The myocardial performance index was higher (higher values indicate impaired LV function) in the patient group compared to the control group (0 38 vs. 0 27; P < 0 05). The LV-GLS was significantly lower in the SCD group than in the control group ( 19 4% vs. 22 4%; P < 0 05), and it was abnormal (strain > 18%) in 8 (21%) patients of the SCD group. Diastolic function was abnormal in three SCD patients (8%), but normal in the entire control group. The tricuspid regurgitation velocity was higher in the SCD group than in the control group (2 24 m/s vs. 1 96 m/s, P < 0 05). However, no patient had pulmonary hypertension. The multivariate analysis results (Table II) showed that only the LV-GLS and LVEDD remained significantly different between groups. Among patients with SCD, the mean Hb was 94 g/l (range: 61–122 g/l) and the mean HbF was 12 7% (range: 1– 28 6%). The mean ferritin level was 644 lg/l (range: 13– 7267 lg/l). Iron overload, defined as a ferritin level greater than 1000 lg/l, was observed in five patients. The mean Nterminal pro b-type natriuretic peptide (NTproBNP) level was 154 pg/ml (range 12–1685 pg/ml). The mean patient walking distance was 66% of the predicted value (range: 33–88%).


Thrombosis Research | 2010

Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay

Marie-Agnès Azerad; Denis F Noubouossie; Laurence Rozen; H. Coenraad Hemker; Francis Corazza; André Efira; Anne Demulder


Thrombosis Research | 2010

PO-54 Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay and an automated procoagulant assay

F. Debaugnies; Marie-Agnès Azerad; Denis F Noubouossie; Laurence Rozen; H.C. Hemker; André Efira; Anne Demulder


Hématologie | 2008

Méningites lymphomateuses : prophylaxie et traitement

Véronique Delrieu; Marie-Christine Ngirabacu; Imran Ahmad; Marie-Agnès Azerad; Nathalie Meuleman; Jean-Louis Dargent; Brigitte Cantiniaux; Dominique Bron


Blood | 2016

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Joep W. R. Sins; Karin Fijnvandraat; Anita W. Rijneveld; Martine B. Boom; Jean-Louis Kerkhoffs; Alfred H. van Meurs; Marco R De Groot; Harriët Heijboer; Marie-Françoise Dresse; Alina Ferster; Philippe Hermans; Anna Vanderfaeillie; Eric Van Den Neste; Fleur Samantha Benghiat; Jo Howard; Rachel Kesse-Adu; André Efira; Marie-Agnès Azerad; Corianne A.J.M. de Borgie; Bart J. Biemond


Gunaïkeia (Ed. française) | 2014

Pregnancy in women with sickle cell disease: Recommendations from the Red-Blood Cell subcommittee of the Belgian Haematology Society

Fleur Samantha Benghiat; Marie-Agnès Azerad; Patricia Barlow; Christine Kirkpatrick; Alina Ferster; Cristina Epalza; Laurence Dedeken; Béatrice Gulbis; Lisa Balepa


Blood | 2014

Does Hemoglobin S in Sickle Cell Trait and Sickle Cell Anemia Induce Higher Hemostatic Potential

Bhavna Mahadeb; Laurence Rozen; Denis F Noubouossie; Tatiana Besse-Hammer; André Efira; Philippe Hermans; Béatrice Gulbis; Marie-Agnès Azerad; Anne Demulder


Revue Médicale de Bruxelles | 2013

Les anémies réfractaires

André Efira; Marie-Agnès Azerad

Collaboration


Dive into the Marie-Agnès Azerad's collaboration.

Top Co-Authors

Avatar

André Efira

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Anne Demulder

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Denis F Noubouossie

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Fleur Samantha Benghiat

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Laurence Rozen

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Alina Ferster

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Anna Vanderfaeillie

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Béatrice Gulbis

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Dominique Bron

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Eric Van Den Neste

Cliniques Universitaires Saint-Luc

View shared research outputs
Researchain Logo
Decentralizing Knowledge